By Elena Vardon
ValiRx said Friday that it isn’t in possession of unpublished price-sensitive information after its share price jumped in early trade.
At 1001 GMT, shares were up 4.60 pence, or 48%, at 14.25 pence, their highest price since early January.
The London-listed life-sciences company said its asset for prostate cancer remains subject to a letter of intent it signed with TheoremRx in November 2021.
It said it also noted that Singapore-based platform EUDA Health Holdings said on Thursday that it had entered into a letter of intent for a proposed merger with TheoremRx.
Write to Elena Vardon at [email protected]
Read the full article here
